Publikationen in Zusammenarbeit mit Forschern von Universitat Autònoma de Barcelona (9)

2020

  1. SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)

    Clinical and Translational Oncology, Vol. 22, Núm. 2, pp. 171-186

2017

  1. Endocrinologist and oncologist, a friendship under construction about obesity

    Endocrinologia, Diabetes y Nutricion, Vol. 64, Núm. 1, pp. 1-3

  2. Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 682-694

  3. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification

    Neuro-Oncology, Vol. 19, Núm. 11, pp. 1522-1531

2016

  1. Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: A Spanish expanded access trial

    Orphanet Journal of Rare Diseases, Vol. 11, Núm. 1

2015

  1. Candidate genetic modifiers for breast and ovarian cancer risk inBRCA1andBRCA2 mutation carriers

    Cancer Epidemiology Biomarkers and Prevention, Vol. 24, Núm. 1, pp. 308-316

2014

  1. Capillary Electrophoresis Analysis of Conventional Splicing Assays: IARC Analytical and Clinical Classification of 31 BRCA2 Genetic Variants

    Human Mutation, Vol. 35, Núm. 1, pp. 53-57

  2. Erratum: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry [J Neurooncol, 116, (2014), 413-419, DOI 10.1007/s11060-013-1316-y]

    Journal of Neuro-Oncology

2012

  1. Characterization of four novel BRCA2 large genomic rearrangements in Spanish breast/ovarian cancer families: Review of the literature, and reevaluation of the genetic mechanisms involved in their origin

    Breast Cancer Research and Treatment, Vol. 133, Núm. 1, pp. 273-283